Publications | Methodology | CRECON R&C Pharmacoeconomics

CRECON R&C TOP

Serial publications

Kobayashi M. The essence of pharmacoeconomics[39] ISPOR 16th Annual International Meeting. Monthly Medical Information Express. 2011;6:90-93. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[38] Pharmacoeconomic evaluation of cancer: (6) Myelodysplastic syndromes (MDS). Monthly Medical Information Express. 2011;6:90-93. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[37] Pharmacoeconomic evaluation of cancer: (5) Breast cancer. Monthly Medical Information Express. 2011;5:88-91. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[36] Pharmacoeconomic evaluation of cancer: (4) Chronic myelogenous leukemia. Monthly Medical Information Express. 2011;4:84-87. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[35] Pharmacoeconomic evaluation of cancer: (3) What lies behind of NICE rejection of cancer drugs? (Renal cancer). Monthly Medical Information Express. 2011;3:80-83. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[34] Pharmacoeconomic evaluation of cancer: (2) What lies behind of NICE rejection of cancer drugs? (Colorectal cancer). Monthly Medical Information Express. 2011;2:80-83. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[33] Pharmacoeconomic evaluation of cancer: (1)Basic information of cancer. Monthly Medical Information Express. 2010;12:68-72. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[32] Breaf report of the ISPOR 4th Asia-Pacific Conference. Monthly Medical Information Express. 2010;11:80-83. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[31] Pharmacoeconomic evaluation of hepatitis C. Monthly Medical Information Express. 2010;10:70-73. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[30] Pharmacoeconomic evaluation of vaccine: (2)HPV vaccine. Monthly Medical Information Express. 2010;9:82-85. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[29] Pharmacoeconomic evaluation of vaccine: (1)Streptococcus pneumococcal vaccine in children. Monthly Medical Information Express. 2010;8:84-87. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[28] Pharmacoeconomic evaluation of glaucoma. Monthly Medical Information Express. 2010;7:104-107. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[27] Pharmacoeconomic evaluation of osteoporosis. Monthly Medical Information Express. 2010;6:98-101. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[26] The role of pharmacoeconomic evaluation after an introduction of new drug creation allowance. Monthly Medical Information Express. 2010;5:80-83. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[25] Pharmacoeconomic evaluation of Rheumatoid Arthritis. Monthly Medical Information Express. 2010;4:76-79. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[24] Pharmacoeconomic evaluation of schizophrenia. Monthly Medical Information Express. 2010;3:96-99. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[23] Pharmacoeconomic evaluation of CKD. Monthly Medical Information Express. 2010;2:90-94. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[22] Pharmacoeconomic evaluation of COPD. Monthly Medical Information Express. 2010;1:76-79. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[21] ISPOR 12th Annual European Congress. Monthly Medical Information Express. 2009;12:82-85. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[20] Pharmacoeconomic evaluation of IGT. Monthly Medical Information Express. 2009;11:80-83. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[19] Pharmacoeconomic evaluation of diabetes mellitus (2). Monthly Medical Information Express. 2009;10:68-71. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[18] Pharmacoeconomic evaluation of diabetes mellitus (1). Monthly Medical Information Express. 2009;9:80-83. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[17] Pharmacoeconomic evaluation of dyslipidemia. Monthly Medical Information Express. 2009;8:78-81. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[16] Pharmacoeconomic evaluation of hypertension. Monthly Medical Information Express. 2009;7:98-101. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[15] Utilization of pharmacoeconomical outcomes in foreign countries for Japan. Monthly Medical Information Express. 2009;6:68-71. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[14] Willingness to pay and conjoint analysis. Monthly Medical Information Express. 2009;5:68-72. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[13] Burden of illness study. Monthly Medical Information Express. 2009;4:64-68. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[12] Budget impact analysis. Monthly Medical Information Express. 2009;3:48-51. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[11] Net-Benefit and value of information. Monthly Medical Information Express. 2009;2:52-56. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[10] Evaluation of cost-effectiveness at IQWiG. Monthly Medical Information Express. 2009;1:38-41. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[9] Evaluation of three treatments or more. Monthly Medical Information Express. 2008;12:46-49. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[8] Sensitivity analysis（2）. Monthly Medical Information Express. 2008;11:44-47. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[7] Sensitivity analysis（1）. Monthly Medical Information Express. 2008;10:50-53. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[6] Evaluation of cost-effectiveness by using a incremental cost-effectiveness ratio. Monthly Medical Information Express. 2008;9:40-43. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[5] How to evaluate cost-effectiveness. Monthly Medical Information Express. 2008;485:52-54. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[4] Model analysis in pharmacoeconomics (2). Monthly Medical Information Express. 2008;7:47-51. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[3] Model analysis in pharmacoeconomics (1). Monthly Medical Information Express. 2008;6:54-58. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[2] The value of drugs. Monthly Medical Information Express. 2008;5:42-45. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[1] Why are economic evaluations of drugs required? Monthly Medical Information Express. 2008;4:38-42. (in Japanese)

Kobayashi M. Modelling technique for pharmacoeconomic analysis [3] - Model analysis by Markov models. Kusuri no chisiki. 2004;55(5):19-23. (in Japanese)

Kobayashi M. Modelling technique for pharmacoeconomic analysis [2] - Model analysis by decision tree. Kusuri no chisiki. 2004;55(4):23-27. (in Japanese)

Kobayashi M. Modelling technique for pharmacoeconomic analysis [1] - Model analysis in pharmacoeconomics analysis. Kusuri no chisiki 2004;55(4):23-27. (in Japanese)

Kobayashi M. Pharmacoeconomics (5). The current medicine. 2003;51(1):145-149. (in Japanese)

Kobayashi M. Pharmacoeconomics (4). The current medicine. 2002;50(3):533-537. (in Japanese)

Kobayashi M. Pharmacoeconomics (3). The current medicine. 2002;50(2):323-327. (in Japanese)

Kobayashi M. Pharmacoeconomics (2). The current medicine. 2002;50(1):143-148. (in Japanese)

Kobayashi M. Pharmacoeconomics (1). The current medicine. 2002;49(3):473-476. (in Japanese)

Kobayashi M. Pharmacoeconomics[3] - Utilization of pharmacoeconomics in sales promotion. Monthly Medical Information Express. 2000;11:78-81. (in Japanese)

Mano T, Kobayashi M. Pharmacoeconomics[1] - Current status of pharmacoeconomics in the United States. Monthly Medical Information Express. 2000;9:102-105. (in Japanese)

Serial publications